A new study suggests that patients with a rare form of melanoma, called desmoplastic melanoma, may be particularly likely to benefit from treatments known as immune checkpoint inhibitors. An NCI-sponsored clinical trial is already testing one such drug in patients with this cancer.
http://ift.tt/2o4MZs3
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου